From: Doug Skrecky (oberon@vcn.bc.ca)
Date: Tue Sep 08 1998 - 20:53:14 MDT
Authors
Friedman EA. Distant DA. Fleishhacker JF. Boyd TA. Cartwright K.
Institution
Department of Medicine, State University of New York, Health Science Center
at Brooklyn, 11203-2098, USA. elifreidmn:aol.com
Title
Aminoguanidine prolongs survival in azotemic-induced diabetic rats.
Source
American Journal of Kidney Diseases. 30(2):253-9, 1997 Aug.
Abstract
Toxic effects of hyperglycemia-induced advanced glycosylated
end products (AGEs) may explain some vasculopathic
complications of diabetes. Aminoguanidine, a known inhibitor of AGE
formation, was administered by gavage to Sprague-Dawley
streptozotocin-induced diabetic rats made azotemic by surgical reduction of
renal mass. All rats became hyperglycemic. Renal ablation caused renal
insufficiency, as evidenced by markedly reduced endogenous
creatinine clearances at days 7 and 14. Aminoguanidine-treated rats had
significantly (P < 0.04) superior survival to that of untreated azotemic
diabetic rats. We infer from the extended life in a rat
model of uremia in diabetic nephropathy that aminoguanidine may prove
beneficial in human diabetes.
This archive was generated by hypermail 2.1.5 : Fri Nov 01 2002 - 14:49:33 MST